$NNVC

NanoViricides, Inc. (NNVC) reported progress in its Phase IIA trial for NV-387 Oral Gummies Ebola in the DRC, targeting 20 patients with a 28-day survival endpoint. The trial is expected to advance to Phase IIB upon completion. The company aims to progress NV-387 across multiple indications, with a clearer catalyst expected upon IIA completion and IIB start.

NanoViricides (NNVC) reports progress in Phase IIA clinical trial of NV-387 Oral Gummies for Ebola treatment; 10,060 confirmed cases and 4,887 deaths in Congo's outbreak. Trial aims to evaluate dosing and 28-day survival. NV-387 is the only oral drug in trials for Ebola Bundibugyo virus.

NanoViricides, Inc. (NNVC) announced that its antiviral drug NV-387 showed strong safety and tolerability in a juvenile mouse study, paving the way for pediatric clinical trials. NV-387 is in Phase II trials for Ebola and Mpox, with potential pediatric cohorts if successful. The company also has plans for a Phase II trial for Measles, which has received Orphan Drug and Rare Pediatric Disease Designations from the FDA.

NanoViricides (NNVC) reports progress in its Phase IIA clinical trial of NV-387 oral gummies for Ebola treatment. The trial aims to evaluate safety and tolerability in patients with varying severity levels of the Bundibugyo Ebola virus in the DRC. As of October 10, 2026, the outbreak has resulted in 4,339 deaths out of 9,000 confirmed cases, according to the WHO. The company expects to announce results on safety and potential efficacy soon.

Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.

NanoViricides (NNVC) began Phase IIA of its NV-387 oral gummies trial for Ebola around Sept. 23, 2026, focusing on setting a tolerable dosing regimen before a Part IIB efficacy study. The company aims to establish a clear dosing regimen and initiate the randomized Part IIB with early efficacy signals.

NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Compensatory Arrangements of Certain Officers. Extension Employment Agreement - Anil Diwan On September 25, 2026, NanoViricides, Inc. (the “Registrant”) entered into an Extension Agreement effective July 1, 2026 (the “Diwan Extension”) of the Employment Agreement with

NanoViricides (NNVC) began Phase II trials of NV-387, a potential monkeypox treatment, in the DRC. The trial, led by Prof. Vivi Maketa, aims to assess safety and efficacy. NV-387 could address unmet needs, as current treatments like tecovirimat and brincidofovir have limitations. Success may position NV-387 for pandemic preparedness and FDA approval, with potential stockpiling contracts.

NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering New York, July 24, 2026 — NanoViricides, Inc. (NYSE American: NNVC) (“NanoViricides” or the “Company”), a clinical stage, leading global pioneer in the development of broad-spectrum antiviral

NanoViricides (NYSE American: NNVC) priced a registered direct offering with a single institutional investor for gross proceeds of about $3.8 million. The company will sell 2,516,339 shares, or pre-funded warrants, plus warrants for the same number of shares at a $1.75 exercise price, expiring about 5.5 years. Closing is expected around July 27, 2026.